Independent educational platform. Not a government website and not the Indian Patent Office. Who we are
MYCrave Consultancy & Services PatentActIndia.comA MYCrave Initiative
Patents ActPatents RulesProcessGuidesToolsForms A–ZForms & FeesCase lawCompareWhat happens if…Who is applyingDeadlinesGlossaryWorked examplesUpdatesSearchSite mapAsk a QuestionMy LibraryConsult MYCrave
PATENTS RULESOmittedChapter V

Rule 51 of the Patents Rules, 2003

Omitted provision

About 3 min read Last reviewed 19 August 2026 Chapter V — Exclusive Marketing Rights (Omitted)
In one line

Rule 51 was one of the Exclusive Marketing Rights rules removed when India moved to product patents, and it now has no operative content.

Official legal text

Official text — Rule 51, the Patents Rules, 2003 Official source ↗
This provision has been omitted.
This provision has been omitted, but its number remains. Statutes here are amended by omission rather than renumbering, which keeps every other number stable. Anyone reading a file, an order or a commentary from the period when it applied will meet this number and need to know what it covered.

This explanation is written for clarity, not for citation. The official statutory text and any Gazette notification in force on your date govern, and they prevail over anything said here.

What this rule requires, step by step

Rule 51 sat inside Chapter V of the Patents Rules, 2003. That chapter existed to service Chapter IVA of the Patents Act, 1970, which allowed the Controller to grant an Exclusive Marketing Right over a medicine or agricultural chemical for a limited period while the country was not yet granting product patents in those fields. The right was narrow. It allowed the holder to sell or distribute the product in India, and it fell away once the underlying patent application was granted or refused, or once the fixed period ran out, whichever happened first. It was never a patent, and it did not carry the full bundle of rights a patent gives.

When the Patents (Amendment) Act, 2005 came into force, Chapter IVA was struck out of the Act because India had begun granting product patents for these products from 1 January 2005. A rule cannot survive without a parent provision to carry out, so the Chapter V rules, Rule 51 among them, were omitted. Anyone who reads this rule number in an old textbook should treat it as closed history. For a live matter, attention should move to how the application itself is published, examined and granted, and to the ordinary rights that follow a grant.

Why this rule matters

Who it affects

Students of Indian patent history, and advisers who encounter Chapter V references in archived files.

When it matters

Only in historical research; it plays no part in any present-day application or dispute.

What it creates

No obligation and no right; the rule was withdrawn with the scheme it served.

If it is ignored

No practical consequence, though quoting it as current law weakens the credibility of any written opinion.

How it works in practice

Worked example

An old marketing right is mistaken for a patent

Nilgiri Biosciences, a Coimbatore company, is preparing to launch a generic version of an older agricultural chemical. A distributor warns that a multinational once held exclusive rights over the same chemical in India and suggests the launch could be blocked. Nilgiri's patent adviser checks the record. The exclusivity referred to was an Exclusive Marketing Right of the kind Chapter V of the Patents Rules once dealt with, not a patent. That scheme ended when the Patents (Amendment) Act, 2005 removed Chapter IVA from the Act, and rules such as Rule 51 were omitted at the same time. The adviser explains that the only question that matters now is whether a granted and unexpired Indian patent covers the product or its process. A register search shows the relevant application was later refused, and no patent stands in the way. Nilgiri proceeds, but the adviser records the search results in writing so that the board has a clear basis for the decision.

Simplified illustration only. Actual legal outcomes depend on the facts.

Key points to remember

  • An Exclusive Marketing Right was a limited selling right, not a patent, and it always had a short life.
  • Rule 51 formed part of the procedure for that right under Chapter V of the Patents Rules, 2003.
  • The right and its rules disappeared when product patents became available in India in 2005.
  • Only a granted, unexpired patent can block a competing product in India today.

Connected provisions

The Patents Rules supply procedure and the Patents Act supplies power. This page covers the procedure, and the sections that give the Controller or the applicant the underlying right or duty are grouped separately so you can move between the two.

Forms, deadlines and fees

Fees

We do not publish fee amounts. The First Schedule sets them, and they differ by category of applicant, such as a natural person, a startup, a small entity or another applicant, and by the mode of filing. Check the Schedule currently in force before you calculate anything. How Indian patent fees work.

Related judgments

Case law is added slowly and deliberately. A summary is drafted, checked against the reported judgment and then reviewed before publication, because a wrong case note can mislead a reader badly. No summary for this provision has reached publication yet. How case notes are prepared.

Questions people ask about Rule 51

Was an Exclusive Marketing Right the same as a patent?

No. A patent gives the owner the right to stop others from making, using, selling, offering for sale or importing the invention in India for the full term of the patent. An Exclusive Marketing Right only allowed the holder to sell or distribute a specific product for a short transitional period, and it ended as soon as the related patent application was granted or refused. It was a temporary commercial cushion during a treaty transition, not a property right in an invention.

Where should I look now for pharmaceutical patent procedure in India?

Use the ordinary route in the Patents Act, 1970 and the Patents Rules, 2003. File the application, watch for publication, file the request for examination in time, respond to the examination report, and deal with any opposition. Sections 3(d) and 3(e) matter a great deal for medicines, and post-grant opposition and revocation remain available to competitors. Nothing from the old Exclusive Marketing Rights chapter feeds into that process.

Is a competitor's Indian patent really blocking you?

MYCrave Consultancy runs register and freedom-to-operate checks so you know what actually stands in your way.

You will be speaking with MYCrave Consultancy & Services, the firm that operates this platform. General questions are answered free; matter‑specific work is quoted before anything is done.